EARLY HEARING DETECTION AND INTERVENTION VIRTUAL CONFERENCE
MARCH 2-5, 2021
(Virtually the same conference, without elevators, airplane tickets, or hotel room keys)
8/23/2022 | 11:20 AM - 11:45 AM | Maternal and Infant Cytomegalovirus Detection Among Women Living with HIV | Governor General III
Maternal and Infant Cytomegalovirus Detection Among Women Living with HIV
Objective: To determine the association between CMV replication in blood collected longitudinally from pregnant women living with HIV (WLWH) and HIV parameters and infant congenital CMV (cCMV) infection. Methods: A prospective cohort study of pregnant WLWH in Canada collected data and specimens at each trimester, delivery, and 4-16w postpartum. Maternal CMV viral load (VL) was measured by qPCR. cCMV was determined through qPCR of infant oral swabs (0-3d). Associations between CMV viremia and HIV parameters were explored using logistic regression. Results: Of 298 pregnant WLWH, 216 were CMV seropositive. At first pregnancy visit, median CD4 count was 531 (IQR: 390-723) cells/mm3 and 114 (53%) had undetectable HIV VL. Of 932 blood specimens, 34 from 28 (13%) women were CMV qPCR positive and neither age nor HIV parameters (baseline/nadir CD4, VL, timing of ART initiation) were associated with CMV viremia. Among 181 infants sampled at 0-3d, one (0.6%) had cCMV infection and the mother of this infant was viremic. Conclusion: Among pregnant CMV seropositive WLWH, 13% had CMV viremia during pregnancy compared to reported rates of ~0.5% in pregnant women without HIV. Nevertheless, the rate of cCMV at birth did not appear elevated.
- Describe the rate of CMV viremia during pregnancy in women living with HIV (WLWH).
- Summarize the relationship between various HIV parameters and maternal CMV viremia in WLWH.
- Discuss the association between maternal CMV viremia and infant congenital infection.
Presentation:
This presentation has not yet been uploaded.
Handouts:
Handout is not Available
Transcripts:
CART transcripts are NOT YET available, but will be posted shortly after the conference
Presenters/Authors
Elisabeth McClymonth
(), Elisabeth.McClymont@cw.bc.ca;
Dr. McClymont is a postdoctoral fellow at the University of British Columbia, Canada with a research focus on reproductive infectious diseases.
ASHA DISCLOSURE:
Financial -
Nonfinancial -